🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Hyalobarrier

    Green Valley (Shanghai) Pharmaceuticals Co.,

    Thyroid Disease

    phase 3 other completed

    1 trial

  2. Hylenex

    HALOZYME THERAPEUTICS, INC.

    Pain

    phase 3 small molecule completed

    1 trial

  3. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 3 other active

    1 trial

  4. IAC regimen

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 3 small molecule completed

    1 trial

  5. IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 75 mg film-coated tablets, IBRANCE 75 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules

    Partner Therapeutics Limited

    Female or male patients with histologically confirmed HR-positive, HER2-negative resected isolated locoregional recurrence (ILRR) of breast cancer.

    phase 3 small molecule active

    1 trial

  6. IBRANCE 125 mg film-coated tablets, Placebo Giredestrant, IBRANCE 100 mg hard capsules, RO7197597, Placebo Letrozole, IBRANCE 75 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg hard capsules, Femara® 2,5 mg Filmtabletten, IBRANCE 100 mg film-coated tablets

    Hoffmann-La Roche

    ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

    phase 3 small molecule active

    1 trial

  7. IBRANCE 75 mg film-coated tablets, GOSERELIN ACETATE, Placebo to match camizestrant, Placebo to match anastrozole, camizestrant, ABEMACICLIB, Placebo to match letrozole, IBRANCE 100 mg film-coated tablets, Arimidex® 1 mg Filmtabletten, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, LETROZOLE, LEUPRORELIN ACETATE, ABEMACICLIB, Camizestrant, ABEMACICLIB

    AstraZeneca AB

    Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  8. IBRUTINIB, PIRTOBRUTINIB, PIRTOBRUTINIB

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  9. IGI, 10%

    Takeda

    Multiple Myeloma

    phase 3 mab active

    1 trial

  10. IM JZP-458

    Jazz Pharmaceuticals Ireland Limited

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  11. IMBRUVICA 140 mg hard capsules, Calquence 100 mg film-coated tablets, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules

    Lacuna Pharma Pty Ltd

    High Risk Chronic Lymphocytic Leukaemia

    phase 3 small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion., DURVALUMAB, MYCOPHENOLATE MOFETIL, Placebo, OncoTICE® powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG., INFLIXIMAB

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  13. IMFINZI 50 mg/mL concentrate for solution for infusion., Futibatinib, Zercepac 150 mg powder for concentrate for solution for infusion., Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets, JZP598, Zejula 100 mg hard capsules, Nerlynx 40 mg film-coated tablets, IVOSIDENIB, CISPLATIN, PEMBROLIZUMAB, GEMCITABINE

    Ningbo Cancer Hospital

    Advanced Biliary Cancer (ABC)

    phase 3 small molecule active

    1 trial

  14. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion., Mycophenolate Mofetil 500 mg film-coated tablets, Nexavar 200 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Advanced hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  15. IMIPENEM, CILASTATIN AND RELEBACTAM, AMIKACIN , TIGECYCLINE , Nacubactam, AZACTAM 1 g, poudre et solution pour usage parentéral, COLISTIN , Cefepime Panpharma, 2 g, proszek do sporządzania roztworu do wstrzykiwań lub infuzji

    Lacuna Pharma Pty Ltd

    Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)

    phase 3 small molecule active

    1 trial

  16. IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, LENVIMA 4 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  17. IMP Placebo, Comparator Placebo, Seretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspension., CHF5993 pMDI (100) -152a

    Chiesi Farmaceutici S.p.A

    Uncontrolled Asthma

    phase 3 small molecule active

    1 trial

  18. IMUKIN 2 X 106 UI (0,1 mg), solution injectable, SODIUM CHLORIDE

    Pari Pharma GmbH

    Post-aggressive immunosuppression

    phase 3 small molecule active

    1 trial

  19. INCA33890, Placebo contains the same formulation buffer, 10 mM acetate, 9% (w/v) sucrose and 0.02% (w/v) polysorbate 80, at pH 5.5, without the active pharmaceutical ingredient., CALCIUM FOLINATE, BEVACIZUMAB, OXALIPLATIN, FLUOROURACIL

    Incyte

    Metastatic Microsatellite Stable Colorectal Cancer

    phase 3 small molecule active

    1 trial

  20. INCLISIRAN, -

    Novartis Pharmaceuticals

    Familial hypercholsterolemia

    phase 3 small molecule active

    1 trial

  21. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Pharmaceuticals

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  22. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Pharmaceuticals

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  23. INEBILIZUMAB, 10 mL (nominal) solution containing 10 mM histidine/histidine hydrochloride, 75 mM sodium chloride, 106 mM (4% [w/v]) trehalose dihydrate, and 0.02% (w/v) polysorbate 80, pH 6.0

    Elan Pharma International

    Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).

    phase 3 small molecule active

    1 trial

  24. INFLIXIMAB , MYCOPHENOLIC ACID , SALINE, ETOPOSIDE , CARBOPLATIN , PEMETREXED , IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN , PACLITAXEL

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources